Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virus-mediated EpoR76E Therapy Slows Optic Nerve Axonopathy in Experimental Glaucoma.

Molecular therapy : the journal of the American Society of Gene Therapy - 1 Feb 2016

Bond Wesley S, Hines-Beard Jessica, GoldenMerry YPaul L, Davis Mara, Farooque Alma, Sappington Rebecca M, Calkins David J, Rex Tonia S

Abstract excerpt

Glaucoma, a common cause of blindness, is currently treated by intraocular pressure (IOP)-lowering interventions. However, this approach is insufficient to completely prevent vision loss. Here, we evaluate an IOP-independent gene therapy strategy using a modified erythropoietin, EPO-R76E, which has reduced erythropoietic function. We used two models of glaucoma, the murine microbead occlusion model and the DBA/2J...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Axons
Share to Dependovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythropoietin

Share to Genetic Therapy

Share to Genetic Vectors

Share to Glaucoma

Share to Intraocular Pressure

Share to Optic Nerve

Source

Open in PubMed Open full text

Identifiers

PMID: 26502777
DOI: 10.1038/mt.2015.198
PMCID: PMC4817814

Genes

EPO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virus-mediated EpoR76E Therapy Slows Optic Nerve Axonopathy in Experimental Glaucoma.PMID 26502777Read ↗

Systemic Adeno-Associated Virus-Mediated Gene Therapy Preserves Retinal Ganglion Cells and Visual Function in DBA/2J Glaucomatous MiceSemantic proximity Read ↗

rAAV prostaglandin-based gene therapy lowers intraocular pressure and preserves optic nerve health in glaucomatous DBA/2J miceSemantic proximity Read ↗

The concept of gene therapy for glaucomaSemantic proximity Read ↗

Pigment Epithelium-Derived Factor Gene Therapy Targeting Retinal Ganglion Cell Injuries: Neuroprotection against Loss of Function in Two Animal ModelsSemantic proximity Read ↗

Activation of the Extracellular Signal-Regulated Kinase 1/2 Pathway by AAV Gene Transfer Protects Retinal Ganglion Cells in GlaucomaSemantic proximity Read ↗

Towards A Microbead Occlusion Model of Glaucoma for a Non-Human PrimateSemantic proximity Read ↗

Dose-ranging and further therapeutic evaluation of a bicistronic humanized TrkB-BDNF gene therapy for glaucoma in rodentsSemantic proximity Read ↗

Upregulation of the endothelin A (ETA) receptor and its association with neurodegeneration in a rodent model of glaucomaSemantic proximity Read ↗

Non-erythropoietic erythropoietin derivatives protect from light-induced and genetic photoreceptor degeneration.Semantic proximity Read ↗

Use of Gene Therapy in Retinal Ganglion Cell Neuroprotection: Current Concepts and Future DirectionsSemantic proximity Read ↗

Systemic but not intraocular Epo Gene Transfer Protects the Retina from Light-and Genetic-Induced DegenerationSemantic proximity Read ↗

OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.